Tag Archives: Actelion

The U.S. FDA Designates Johnson & Johnson’s Cadazolid An Orphan Drug For Treatment of C.diff. Infection in Pediatric Patients

The FDA designates Johnson & Johnson’s

cadazolid an Orphan Drug for the treatment of

Clostridium difficile (C. diff) infection

in pediatric patients.



Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

Cadazolid is a quinoxolidinone antibiotic being developed by Actelion.






Aug. 9, 2017 7:40 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor